CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.65B, above the global median of $1.18B
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)
- Interpretations4 currently firing — 1 · 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.23%
Annual Rate
CNY 0.80Paid annual
Payout Ratio
419.7%High
Payback Period
25.1 yr
Last Ex-Dividend
Jun 15, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.05BCNY1.65B · vs all stocks (USD)
Trailing P/E
55.70xvs Biotechnology peers
Revenue (TTM)
1.19BCNY177.11M · vs all stocks (USD)
Profit Margin
16.73%vs Biotechnology peers
Beta
0.5990xvs all stocks
52-Week Change
8.86%vs all stocks
Market Capitalization
11.05BCNY1.65B · vs all stocks (USD)
Enterprise Value
7.88BCNY1.18B · vs all stocks (USD)
Trailing P/E
55.70xvs Biotechnology peers
Forward P/E
44.00xvs Biotechnology peers
Price to Sales (TTM)
9.31xvs Biotechnology peers
Price to Book (MRQ)
1.92xvs Biotechnology peers
Enterprise to Revenue
6.63xvs Biotechnology peers
Enterprise to EBITDA
29.93xvs Biotechnology peers
Profit Margin
16.73%vs Biotechnology peers
Return on Assets (TTM)
1.15%vs Biotechnology peers
Return on Equity (TTM)
3.55%vs Biotechnology peers
Revenue (TTM)
1.19BCNY177.11M · vs all stocks (USD)
Revenue per Share (TTM)
1.99CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-50.60%vs Biotechnology peers
Gross Profit (TTM)
853.92MCNY127.42M · vs all stocks (USD)
EBITDA (TTM)
407.77MCNY60.85M · vs all stocks (USD)
Net Income (TTM)
198.57MCNY29.63M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-27.48%vs Biotechnology peers
Operating Cash Flow (TTM)
417.36MCNY62.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
299.14MCNY44.64M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.8000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
4.23%vs all stocks
Payout Ratio
419.66%vs Biotechnology peers
Revenue
1.20BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
266.94MCNYFY2025 · Dec 31, 2025Gross Profit
935.56MCNYFY2025 · Dec 31, 2025Operating Income
187.60MCNY27.99M · vs all stocks (USD)
Pre-tax Income
187.79MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.87MCNYFY2025 · Dec 31, 2025Net Income
182.92MCNYFY2025 · Dec 31, 2025EBIT
190.34MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
407.77MCNYFY2025 · Dec 31, 2025Research & Development
151.30MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
566.09MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.55MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3074CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3074CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
595.05MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
595.05MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
182.92MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
254.30MCNYFY2025 · Dec 31, 2025Free Cash Flow
244.79MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
352.94MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
182.92MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.60MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
91.66MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.88MCNYFY2025 · Dec 31, 2025Capital Expenditures
-9.52MCNYFY2025 · Dec 31, 2025Purchase of Investments
-7.90BCNYFY2025 · Dec 31, 2025Sale of Investments
8.09BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
180.54MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-300.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-507.89MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-807.89MCNYFY2025 · Dec 31, 2025Shares Outstanding
601.03MSharesUpdated Sep 21, 2026Float Shares
97.10MSharesUpdated Sep 21, 2026% Held by Insiders
83.17%vs all stocks
% Held by Institutions
0.69%vs all stocks
Total Cash (MRQ)
3.06BCNY456.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.14CNYUpdated Sep 21, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
4.42xvs Biotechnology peers
Book Value per Share (MRQ)
9.59CNYUpdated Sep 21, 2026Total Assets
6.84BCNY1.02B · vs all stocks (USD)
Total Current Assets
4.38BCNYFY2025 · Dec 31, 2025Total Liabilities
1.14BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.46BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
22.95MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.12BCNYFY2025 · Dec 31, 2025Cash
352.94MCNYFY2025 · Dec 31, 2025Cash Equivalents
252.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
352.94MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.97BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.35BCNYFY2025 · Dec 31, 2025Inventory
179.20MCNYFY2025 · Dec 31, 2025Accounts Payable
60.98MCNYFY2025 · Dec 31, 2025Other Current Liabilities
65.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
601.03MCNYFY2025 · Dec 31, 2025Retained Earnings
2.00BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.70BCNY851.19M · vs all stocks (USD)
Treasury Stock
106.79MCNYFY2025 · Dec 31, 202552-Week Low
15.43CNYUpdated Sep 21, 202652-Week High
27.88CNYUpdated Sep 21, 202652-Week Change
8.86%vs all stocks
Beta
0.5990xvs all stocks
50-Day MA
17.66CNYUpdated Sep 21, 2026200-Day MA
18.93CNYUpdated Sep 21, 2026Avg 10-Day Volume
7.91MSharesUpdated Sep 21, 2026Avg 30-Day Volume
8.26MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.3300CNYUpdated Sep 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 193
Financial Health
Altman Z-Score 7.06: safe zoneNotable
Altman Z-Score: 7.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.65B, above the global median of $1.18BNotable
Market cap (USD): 1,648,416,246.849Global Median: 1,180,223,658.953
Levered free cash flow is $44.64M, above the global median of $18.73MNotable
Levered free cash flow (USD): 44,637,069.145Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hebei Broadcasting & TV Information Network Co. Ltd.
4 interpretationsHigh Dividend Payout With FCF And Equity RatioMinimal Tax and Interest DragCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Allied Supreme Corporation
2 interpretationsHigh Dividend Payout With FCF And Equity RatioCash-Flow Ratios Elevated
Concord Biotech Ltd.
2 interpretationsCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated